Consistent with this, reduced CLDN5 expression and associated disruption to the BBB at the tight junctions is associated with numerous neurological conditions including traumatic brain injury sequela, Alzheimer’s disease, cognitive decline, multiple sclerosis, epilepsy, and stroke (Greene et al., 2019; Hashimoto et al., 2023). Here, CLDN5 is linked to Alzheimer disease.